$1.240
+0.031 (+2.48%)Al cierre
Noticias de CODX
Eventos de CODX
Co-Diagnostics Announces First International Deployment of Mosquito Surveillance Platform
Co-Diagnostics announced the first international deployment of its Vector Smart mosquito surveillance platform, to include shipments of laboratory equipment, consumables, and other mosquito abatement reagents and materials to an overseas United States Air Force base.
Selling Stockholders Plan to Sell 3.4M Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.4M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Co-Diagnostics Submits Dual 510(k) Application to FDA
Co-Diagnostics announced that it has submitted a Dual 510(k) premarket notification, with a concurrent CLIA Waiver by Application, to the U.S. FDA for the Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument. The submission follows the company's previously announced completion of the clinical and analytical performance studies supporting the test.
Co-Diagnostics and CoSara Complete Ebola Test Proof of Concept
Co-Diagnostics announced that CoSara Diagnostics, the company's joint venture in India, has sent test kits of the Saragene Bundibugyo Virus Test to a third-party laboratory for evaluation following a request by the India Centre for Cellular and Molecular Platforms, an initiative supported by the India Department of Biotechnology. The company also announced successful completion of a proof-of-concept study evaluating an extraction-free Co-Primers Ebola test on the Co-Dx PCR Pro instrument using diluted plasma as a sample type. This feasibility work represents the first blood-borne assay designed for use on the PCR Pro point-of-care instrument. The analytical studies were initiated following a request by C-CAMP for 200 of CoSara's Bundibugyo tests.
Co-Diagnostics Appoints Wes Lindsey as Chief Scientific Officer
Co-Diagnostics appointed Wes Lindsey as its new Chief Scientific Officer. Lindsey holds a PhD in Genetics & Molecular Biology from Emory University and an MBA from Georgia State University. Over his career, Lindsey has led assay development and R&D teams that produced more than a dozen FDA 510(k) submissions and CE-marked assays for sample-to-result in vitro diagnostic products.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.